Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma

Inclusion Criteria (B-CAP): * classical Hodgkin Lymphoma * Age 60 years or older * ECOG performance status ≤ 2 or ≤ 3 if due to HL * CIRS-G score of ≤ 6 and ≤ 3 per organ system (except score 4 for eye, ear, nose and throat) * Advanced stages: Stage IIB with large mediastinal mass and/or extranodal lesions, stage III or IV disease * written informed consent Exclusion Criteria (B-CAP): * Composite lymphoma or nodular lymphocyte- predominant Hodgkin lymphoma (NLPHL) * Prior chemotherapy or radiation for HL except prephase * Peripheral neuropathy greater than CTC Grade 1 Inclusion Criteria (BV only): * classical Hodgkin Lymphoma * Age 60 years or older * stage IA to IVB * CIRS-G score of ≥ 7 or 4 in one organ system (except score 4 for eye, ear, nose and throat) * Patients not eligible to curative poly-chemotherapy at the investigators judgment * written informed consent Exclusion Criteria (BV only): * Composite lymphoma or nodular lymphocyte- predominant Hodgkin lymphoma (NLPHL) * Prior chemotherapy or radiation for HL except prephase as outlined in the protocol * Peripheral neuropathy greater than CTC Grade 1